Natural Capsules Ltd share Price

Natural Capsules Limited is a pharmaceutical company that manufactures hard dosage capsules, hard cellulose capsule shells, and pharmaceutical dosage forms. The company, founded in 1993, carries out manufacturing activities related to pharmaceutical products. Its registered office is in Bengaluru. The company meets all compliance and statutory requirements relating to cGLP and cGMP practices as ordained by the government of India.

On 19 December 2022, the market capitalisation of the company was Rs 450.72 crore.  It reported a total income of Rs 45.13 crore at the end of September 2022. The company is listed on the Bombay Stock Exchange with the code 890161 and not listed on the NSE.  

Natural Capsules has a diversified shareholding pattern, with promoters holding approximately 56.56% of the company. The public has a stake of 42.2% in the company. FII and mutual funds do not hold any stake in the company (as of November 2022). The shareholding pattern of the company has remained largely stable over the past year.

Sunil Laxminarayan Mundra is the current managing director of the company. Other directors of the company include CP Rangachar, Laxminarayan Mundra, Satyanarayana Mundra, Jyothi Mundra, Sushil Kumar Mundra, S G Belapure, and Pramod Kasat. The chief financial officer of Natural Capsules is R K Prasad. The company’s auditors are P Chandrasekar LLP.  

On 19 December 2022, Natural Capsule’s share price was Rs 487.75 on the BSE. As mentioned earlier, the company is not listed on the National Stock Exchange. The company’s 52-week-high was Rs 679, while the 52-week-low was Rs 255. Its three-month return to investors was -16.05%, while its one-year return was 83.64%.

The company’s peers include Fredun Pharma, Medico Remedies, and Fermenta Biotech.

The total income of the company was Rs 45.13 crores during the quarter ended September 2022. The basic EPS of the company was 21.1 during the same time frame. The company’s total expenses were Rs 37.4 crore during that quarter. The company’s EBIT stood at Rs 7.73 crores, while the EBIT growth was 0.13%. The net profit margin was 11.7%.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.